Study ID: CTSU C30901

Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression after First-Line Chmeotherapy


The main purpose of this study is to find out whether continuation of chemotherapy with pemetrexed will increase the time before the mesothelioma begins to grow again. Pemetrexed is approved by the FDA to treat mesothelioma, but exactly how long to continue pemetrexed is not known. Participants in this study have already been treated for malignant mesothelioma with chemotherapy (pemetrexed with cisplatin or carboplatin). While receiving that treatment, the tumor has either stayed the same or gotten smaller. It is not known whether patients whose tumor has not grown should continue on the chemotherapy, or whether patients would benefit from a break in treatment.

Bismarck Region
Principal Investigator:
Preston Steen, MD
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list